Are current investments in medical research focusing on unmet health needs? Virtual event
Discover the new treatments that will transform the lives of patients over the next five to ten years
The EFPIA Pipeline Review has found that in 2020 alone, around 5,000 clinical trials were initiated to investigate and develop new therapies and vaccines. Almost 50% of therapies in development are new substances, with 40% of the pipeline targeting rare diseases, and groundbreaking cell and gene therapies growing in importance.
This exciting new wave of medical innovation will play a key role in addressing the challenges faced by patients and healthcare systems.
How can we optimise the introduction of new treatments into health systems?
To coincide with the publication of EFPIA’s annual “Pipeline Review”, we are organising a high-level panel discussion around the latest medical research outcomes. Representatives from patient organisations, EU institutions, and industry will share their perspectives on:
- Are current investments in medical research focusing on unmet health needs?
- How is the patient perspective included in the research and development of new therapies?
- How will the EU Pharmaceutical Strategy strengthen Europe as a true hub for medical innovation in the face of fierce global competition?
We look forward to virtually seeing you on 26 March from 16:30 - 18:00 CET!